Background Non-human leukocyte antigen (non-HLA) antibodies including antibodies
targeting Angiotensin II type 1 (AT1R) and Endothelin-1 type A (ETAR) receptors represent a …

Background Studies prospectively monitoring de novo donor-specific antibodies (dnDSAs)
and their clinical impact are sparse. This substudy of ATHENA was initiated to evaluate the …

Background Conversion to everolimus is often used in kidney transplantation to overcome
calcineurin inhibitor (CNI) nephrotoxicity but there is conflicting evidence for this approach …

Abstract Background Non-HLA antibodies (Abs) targeting vascular receptors are considered
to have an influence on renal transplant injury. Anti-endothelin-1 type A receptor (anti-ETAR) …

Background Everolimus (EVR) is used in organ transplantation to minimize calcineurin
inhibitors (CNI). Some studies pointed out an increase in rejection and de novo donor …

Introduction: Kidney transplant recipients from HLA-identical living donor have lower risk of
acute rejection and greater graft survival compared to other types of kidney transplantation …

In a 24‐month, multicenter, open‐label, randomized trial, 715 de novo kidney transplant
recipients were randomized at 10–14 weeks to convert to everolimus (n= 359) or remain on …

Background Immunosuppression with calcineurin inhibitors remains the mainstay of
treatment after kidney transplantation; however, long-term use of these drugs may be …

We aimed to assess the correlation of anti‐angiotensin II type 1 receptor antibodies (anti‐AT
1R‐Abs) before transplantation on a multicentric cohort of kidney transplant recipients (2008 …

Background Everolimus permits reduced calcineurin inhibitor (CNI) exposure, but the
efficacy and safety outcomes of this treatment after kidney transplant require confirmation …